Human Milk Oligosaccharides (HMO) Market

Human Milk Oligosaccharides (HMO) Market by Type (2’ Fl, 3’ Fl, 3’ Sl, 6’ Sl), Application (Infant Formula, Functional Food & Beverages, Food Supplement), Concentration (Acidic, Neutral) & Region (North America, Europe, APAC, South America, RoW) - (2022 – 2027)

Report Code: FB 8086 Apr, 2022, by marketsandmarkets.com

[226 Pages Report] The global Human Milk Oligosaccharides (HMO) Market size is estimated to be valued at USD 199 million in 2022. It is projected to reach USD  556 million by 2027, recording a CAGR of 22.7% during the forecast period.

HMOs as an functional ingredient extracted from human breast milk act as inflammatory and immune modulators. They act as nutrients for the neurological development of infants. The increase in the application of HMOs in functional foods and rising demand in infant formula have led to the growth of the HMOs market. Over the past few years, people have become health-conscious, which has resulted in thorough changes to their lifestyles and diets. People are now more inclined toward functional foods, such as dietary supplements and probiotics. However, the high cost of production is a hindrance to the growth of the global Human Milk Oligosaccharides (HMO) Market.

Human Milk Oligosaccharides (HMO) Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of COVID-19

The COVID-19 pandemic has created a negative impact on the Human Milk Oligosaccharides (HMO) Market. Due to the stringent limitations on movement, the industry faced a severe workforce crisis in manufacturing facilities, research and development units, and logistics. The restricted movement caused a delay in the procurement of raw materials, which impacted the processing and manufacturing of finished products. Many manufacturers witnessed the spoilage and wastage of raw materials, which impacted the production process. There was a severe labor crisis in the distribution channels across the supply chain at each level, which limited the supply of finished products to retail platforms.

End-user manufacturers offering final products consisting of human milk oligosaccharides (infant formula, baby food, and dietary supplements), were able to generate enough profit by rigorous promotion of their products under the umbrella of immunity-boosting nutrition provision. A lot of marketing initiatives, virtual campaigns, workshops, and media advertisements, with more investments in mass production and distribution channels, were adopted by giant players for capturing a large share of the market.

HMO Market Dynamics

Drivers: Rise in infant population

The UN data suggests that over 250 babies are born per minute globally. An average of 353,000 babies are born per day, making the total count of babies born in a year more than 130 million. This directly results in the rise in the consumption of infant formulas at a global level. Several other factors are also responsible for this increased consumption. Some of these include a rise in the number of working women post-giving birth, the inability of mothers to lactate, and better nutrition options for growing infants. According to the UN, the global population is projected to reach 9.6 billion by 2050. Human milk oligosaccharides are used as a major ingredient in the infant nutrition industry for manufacturing various infant formula and baby food. This constantly expanding population is expected to boost the sales of human milk oligosaccharides as an infant formula ingredient in the coming years. According to the National Bureau of Statistics of China, the country recorded 15.23 million births in 2018, creating a lucrative opportunity for manufacturers. Thus, China is expected to be a key revenue generator for the HMO market.

Restraints: High production cost associated with development of HMO-composed supplements and food products

The development and commercial aspects of HMO products are complex, expensive, and uncertain. Factors behind product development success are technological conditions, consumer demand, and legislative and regulatory background. Substantial investment is required for the R&D of a particular type of HMO to be used to produce dietary supplements or other functional food such as prebiotics. These products are developed and produced in accordance with international food regulations. Also, highly sterilized and technical equipment and processes are required to manufacture and extract various other functional ingredients. As a result of the high cost of production, the price of the final product is also high. Marketing and distribution further add to the product price. Although consumers are aware of the health benefits of these expensive functional food products, their high prices restrict them from buying the product. The intensity of the factor further increases in developing countries with a price-sensitive consumer base, especially in some Asian and African countries.

Opportunities: Emergence of alternative animal milk oligosaccharides

Bovine milk oligosaccharides are expected to play a key role in infant nutrition. A laboratory study by RMIT University (Australia), published in the British Journal of Nutrition, suggested that goat milk infant formula had similar prebiotic properties to breast milk and is expected to play a key role in the gut health of infants. Ausnutria Nutrition BV (Netherlands) offers goat milk-based infant formulas under its brand, Kabrita.

Another animal source is camel milk. In 2018, a UAE-based company, the Emirates Industry for Camel Milk and Products, also known as ‘Camelicious,’ launched a camel milk-based baby formula containing a high amount of iron for babies aged 1–3 years. Thus, these sources of animal milk oligosaccharides are expected to gain acceptance in the infant formula ingredients markets in the coming years. rigorous regulatory requirements in the environmental protection sector apply to the manufacturers’ production processes and their production environment

Challenges: Complex industrial process to extract oligosaccharides from milk

One of the biggest challenges associated with developing large-scale or industrial processes to recover oligosaccharides from mammalian milk is achieving a high degree of purity. More specifically, the challenge is to remove simple sugars such as lactose, glucose, and galactose that lack prebiotic activities and might have adverse effects while simultaneously maximizing product recovery. The use of lactose hydrolysis combined with membrane filtration to recover oligosaccharides from milk was successful; however, as the process remains tedious, there is a need to introduce much more advanced and convenient techniques through rigorous techniques research and development activities.

Human Milk Oligosaccharides (HMO) Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Asia Pacific dominated the Human Milk Oligosaccharides (HMO) Market, with a value of USD 92.6 million in 2021; it is projected to reach USD 321.8 million by 2027, at a CAGR of 23.2% during the forecast period.

Asia Pacific consisting of countries like China, India, Japan, Australia & New Zealand and Others is found to dominate the HMO market with presence of large consumer base for HMO derivative products. The region is densely populated with countries like China and India, witnessing a rapid rise in infant population every year. This tendency of population rising is influencing the infant formula market where HMO is used as a vital ingredient for formulating infant foods and other supplements.

New Zealand is one of the major exporters of infant formulas to China, which generates high revenue for the country; hence, the market of HMO-based infant formulas in New Zealand is expected to witness substantial growth during the forecast period. Japan is expected to witness gradual growth in the HMO market, due to the decline in birth rates in recent years. According to an article published by the World Economic Forum in January 2022, the number of births recorded in Japan in 2020 stood at 840,832, which is 2.8% lower than in 2019 and the lowest since 1899.

Key Market Players

The key players in the Human Milk Oligosaccharides (HMO) Market include DSM (Netherlands), BASF SE (Germany), Chr. Hansen Holding A/S (Denmark), DUPONT ( US), and Royal FrieslandCampina N.V. (Netherlands).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size estimation

2022–2027

Base year considered

2021

Forecast period considered

2022–2027

Market Size Value in 2022

USD 199 million

Revenue Forecast in 2027

USD 556 million

Growth Rate

CAGR of 22.7% from 2022 to 2027

Units considered

Value (USD), Volume (KT)

Segments covered

By Type, Application and Concentration

Regions covered

North America, Europe, Asia Pacific, South America and RoW

Companies studied

  • DSM (Netherlands)
  • BASF SE (Germany)
  • CHR Hansen Holding A/S (Denmark)
  • DUPONT (US)
  • Nestle (Switzerland)
  • Biosynth Carbosynth (US)
  • Inbiose N.V (Belgium)
  • Gnubiotics Sciences S.A ( Switzerland)
  • Abbott Laboratories (US)
  • Royal Friesland Campina N.V (Netherlands)
  • Elicityl S.A (France)
  • Dextra Laboratories (UK)

This research report categorizes the Human Milk Oligosaccharides (HMO) Market, based on type, application, concentration and region

Target Audience

  • HMO raw material suppliers
  • HMO manufacturers
  • Intermediate suppliers, such as traders and distributors of HMO
  • Manufacturers of infant formula, functional food and beverages, dietary supplements etc.
  • Government and research organizations
  • Associations, regulatory bodies, and other industry-related bodies:
    • World Health Organization (WHO)
    • European Food Safety Authority (EFSA)
    • U.S. Food and Drug Administration
    • Environmental Protection Agency

By Type

  • 2’ FL
  • 3’ FL
  • 3’ SL
  • 6’ SL

By Application

  • Infant Formula
  • Functional Food & Beverages
  • Food Supplements
  • Other Applications*

By Concentration

  • Neutral
  • Acidic

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Rest of the World (RoW)**

*Other Applications include Clinical Nutrition and Pharmaceuticals.

**Rest of the World (RoW) includes the Middle East and Africa.

Recent Developments

  • In August 2021, Nestle launched the new NAN SUPREME PRO 3 formula products with five human milk oligosaccharides (2’-FL, DFL, LNT, 3’-SL, and 6’-SL), which it claims enhance children’s immunity systems.
  • In September 2020, Chr. Hansen acquired Jennewein Biotechnologie GmbH and a strong patent portfolio relating to the production of human milk oligosaccharides (HMOs) and several litigations related hereto.
  • In May 2019, BASF and Glycosyn signed a partnership agreement for the development and commercialization of human milk oligosaccharides (HMOs) for broad use in dietary supplements, functional nutrition, and medical food.
  • In February 2019, DuPont Nutrition & Health and Lonza Specialty Ingredients announced an agreement under which Lonza will manufacture and supply CARE4U 2’-FL—a human milk oligosaccharide (HMOs). The development of HMOs is part of a larger microbiome investment strategy for DuPont, and central to this is developing scalable production
  • In December 2018, Royal FrieslandCampina N.V. completed the acquisition of a Spain-based distributor, Millan Vicente, which would help it grow its presence in the infant formula ingredients market in Spain.

FAQs:

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 STUDY SCOPE
          FIGURE 1 MARKET SEGMENTATION
          TABLE 1 INCLUSIONS AND EXCLUSIONS
    1.4 REGIONS COVERED
    1.5 PERIODIZATION CONSIDERED
    1.6 CURRENCY CONSIDERED
          TABLE 2 USD EXCHANGE RATES CONSIDERED, 2017–2021
    1.7 UNITS CONSIDERED
    1.8 STAKEHOLDERS
    1.9 INTRODUCTION TO COVID-19

2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA
          FIGURE 2 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primary interviews
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
          FIGURE 4 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SIZE ESTIMATION, BY TYPE (SUPPLY-SIDE)
          FIGURE 5 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SIZE ESTIMATION (DEMAND-SIDE)
           2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    FIGURE 6 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.2 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
                    FIGURE 7 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    2.3 DATA TRIANGULATION
          FIGURE 8 DATA TRIANGULATION
    2.4 ASSUMPTIONS FOR THE STUDY
    2.5 RESEARCH LIMITATIONS & ASSOCIATED RISKS
    2.6 MARKET SCENARIOS CONSIDERED FOR THE IMPACT OF COVID-19
           2.6.1 SCENARIO-BASED MODELLING
    2.7 COVID-19 HEALTH ASSESSMENT
          FIGURE 9 COVID-19: GLOBAL PROPAGATION
          FIGURE 10 COVID-19 PROPAGATION: SELECT COUNTRIES
    2.8 COVID-19 ECONOMIC ASSESSMENT
          FIGURE 11 REVISED GROSS DOMESTIC PRODUCT FORECASTS FOR SELECT G20 COUNTRIES IN 2020
           2.8.1 COVID-19 ECONOMIC IMPACT—SCENARIO ASSESSMENT
                    FIGURE 12 CRITERIA IMPACTING GLOBAL ECONOMY
                    FIGURE 13 SCENARIOS IN TERMS OF RECOVERY OF GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 46)
    TABLE 3 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SNAPSHOT, 2022 VS. 2027
    FIGURE 14 HUMAN OLIGOSACCHARIDES MARKET, BY TYPE, 2022 VS. 2027
    FIGURE 15 HUMAN OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022 VS. 2027
    FIGURE 16 HUMAN OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022 VS. 2027
    FIGURE 17 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET : REGIONAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 ATTRACTIVE OPPORTUNITIES IN THE GLOBAL MARKET
          FIGURE 18 HUMAN MILK OLIGOSACCHARIDES IMPART MEMORY ENHANCEMENT, GUT HEALTH MAINTENANCE, AND BRAIN DEVELOPMENT TO INFANTS
    4.2 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION
          FIGURE 19 ASIA PACIFIC EXPECTED TO DOMINATE THE GLOBAL MARKET BY 2027 IN TERMS OF VALUE
          FIGURE 20 ASIA PACIFIC EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD, BY VOLUME TERMS
    4.3 MARKET, BY TYPE
          FIGURE 21 2’FL SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SIZE DURING THE FORECAST PERIOD BY VALUE TERMS
          FIGURE 22 MARKET FOR 2’FL-BASED HMOS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SIZE BY 2027 IN TERMS OF VOLUME
    4.4 HMO MARKET, BY CONCENTRATION
          FIGURE 23 NEUTRAL HUMAN MILK OLIGOSACCHARIDES SEGMENT EXPECTED TO ACCOUNT FOR A LARGER SIZE DURING THE FORECAST PERIOD
    4.5 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION
          FIGURE 24 DEMAND FOR HMOS IN INFANT FORMULA APPLICATION EXPECTED TO BE THE HIGHEST DURING THE FORECAST PERIOD
    4.6 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY TYPE & KEY COUNTRY
          FIGURE 25 CHINA AND 2’FL MARKET SEGMENTS ACCOUNTED FOR A SIGNIFICANT SHARE IN THE HUMAN MILK OLIGOSACCHARIDES MARKET
          FIGURE 26 CANADA, THE US, MEXICO, AND CHINA EXPECTED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION
    5.2 MACROECONOMIC INDICATORS
           5.2.1 DIGITALIZATION OF THE RETAIL INDUSTRY
                    FIGURE 27 EU: ONLINE PURCHASES OF GOODS & SERVICES, 2018
           5.2.2 RISE IN THE NUMBER OF DUAL-INCOME HOUSEHOLDS
                    FIGURE 28 US: EMPLOYMENT STATUS OF PARENTS WITH CHILDREN UNDER 18 YEARS, 2020
           5.2.3 RAPID URBANIZATION ACROSS REGIONS
                    FIGURE 29 URBAN AND RURAL POPULATIONS IN THE WORLD, 2016–2020
    5.3 MARKET DYNAMICS
          FIGURE 30 MARKET DYNAMICS
           5.3.1 DRIVERS
                    5.3.1.1 Rise in the infant population
                                FIGURE 31 GROWTH IN INFANT POPULATION, 2010–2020 (THOUSAND)
                    5.3.1.2 Growth in health awareness leading to increased consumption of dietary supplements
                                FIGURE 32 US: DIETARY CONSUMPTION RATE, BY AGE GROUP, 2020
                    5.3.1.3 Extensive R&D initiatives by companies operating in the infant formula market
           5.3.2 RESTRAINTS
                    5.3.2.1 Higher production costs associated with the development of HMO-composed supplements and food products
                    5.3.2.2 Stringent regulations and trade policies in the infant formula and dietary supplement industries
           5.3.3 OPPORTUNITIES
                    5.3.3.1 Emergence of alternative animal milk oligosaccharides
                    5.3.3.2 Adoption of advanced technologies in the functional food industry
           5.3.4 CHALLENGES
                    5.3.4.1 Complex industrial process to extract oligosaccharides from milk
                    5.3.4.2 Lack of consumer awareness regarding benefits associated with HMO-formulated products
    5.4 KEY CONFERENCES & EVENTS
          TABLE 4 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023
    5.5 KEY STAKEHOLDERS & BUYING CRITERIA
           5.5.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
                    TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 MODES OF APPLICATIONS
           5.5.2 BUYING CRITERIA
                    FIGURE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
                    TABLE 6 KEY BUYING CRITERIA FOR TOP 3 MODES OF APPLICATION

6 INDUSTRY TRENDS (Page No. - 66)
    6.1 OVERVIEW
    6.2 REGULATORY FRAMEWORK
    6.3 NORTH AMERICA
           6.3.1 CANADA
           6.3.2 US
           6.3.3 MEXICO
    6.4 EUROPEAN UNION (EU)
    6.5 ASIA PACIFIC
           6.5.1 JAPAN
           6.5.2 CHINA
           6.5.3 INDIA
           6.5.4 AUSTRALIA & NEW ZEALAND
    6.6 SOUTH AMERICA
           6.6.1 BRAZIL
           6.6.2 ARGENTINA
    6.7 REST OF THE WORLD (ROW)
           6.7.1 MIDDLE EAST
    6.8 REGULATORY BODIES
    6.9 PATENT ANALYSIS
          FIGURE 34 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: PATENT ANALYSIS, BY APPLICANT, 2017–2021
          FIGURE 35 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: PATENT ANALYSIS, BY REGION, 2017–2021
          FIGURE 36 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: PATENT ANALYSIS, BY LEGAL STATUS, 2017–2021
          TABLE 7 RECENT PATENTS GRANTED WITH RESPECT TO HMOS
    6.10 VALUE CHAIN ANALYSIS
           FIGURE 37 VALUE CHAIN ANALYSIS
    6.11 COVID-19 IMPACT ON THE HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET
    6.12 TREND/DISRUPTION IMPACTING BUYERS IN THE HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET
           FIGURE 38 REVENUE SHIFT FOR THE HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET
    6.13 MARKET ECOSYSTEM
           TABLE 8 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: ECOSYSTEM
    6.14 TECHNOLOGY ANALYSIS
           6.14.1 HIGH-PERFORMANCE ANION-EXCHANGE CHROMATOGRAPHY FOR HUMAN MILK OLIGOSACCHARIDES ANALYSIS
           6.14.2 CAPILLARY ELECTROPHORESIS FOR HUMAN MILK OLIGOSACCHARIDES ANALYSIS
    6.15 PORTER’S FIVE FORCES ANALYSIS
           TABLE 9 PORTER’S FIVE FORCES ANALYSIS
           6.15.1 INTENSITY OF COMPETITIVE RIVALRY
           6.15.2 BARGAINING POWER OF SUPPLIERS
           6.15.3 BARGAINING POWER OF BUYERS
           6.15.4 THREAT OF SUBSTITUTES
           6.15.5 THREAT OF NEW ENTRANTS
    6.16 CASE STUDY ANALYSIS
           6.16.1 USE CASE 1: LAYER ORIGIN INTRODUCED EASY-TO-USE AND EFFICIENT-TO-HMO PREBIOTIC PILLS AND POWDER FOR ADULTS
    6.17 PRICE ANALYSIS
           6.17.1 INTRODUCTION
           6.17.2 PRICE ANALYSIS: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017-2021 (USD PER/KG)
           6.17.3 PRICE ANALYSIS: HMO MARKET, BY REGION, 2017-2021 (USD PER/KG)

7 HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE (Page No. - 80)
    7.1 INTRODUCTION
          FIGURE 39 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
                    TABLE 10 HMO MARKET, BY TYPE, 2017–2021 (TONS)
                    TABLE 11 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
                    TABLE 12 HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
                    TABLE 13 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
           7.1.1 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: COVID-19 IMPACT ANALYSIS, BY TYPE
                    TABLE 14 REALISITIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY TYPE, 2017–2022 (USD MILLION)
                    TABLE 15 OPTIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY APPLICATION, 2017–2022 (USD MILLION)
                    TABLE 16 PESSIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY APPLICATION, 2017–2022 (USD MILLION)
    7.2 2’FL
           7.2.1 AUTHORIZATION OF HMOS BY GOVERNMENT BODIES FOR CONSUMPTION
                    TABLE 17 2’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 18 2’FL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
                    TABLE 19 2’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2017–2021 (TONS)
                    TABLE 20 2’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (TONS)
    7.3 3’FL
           7.3.1 PREBIOTIC QUALITY OF 3’FL EXPECTED TO PROPEL THE GROWTH OF THE HUMAN MILK OLIGOSACCHARIDES MARKET IN THE UPCOMING YEARS
                    TABLE 21 3’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2017–2021 (USD MILLION)
                    TABLE 22 3’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (USD MILLION)
                    TABLE 23 3’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2017–2021 (TONS)
                    TABLE 24 3’FL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (TONS)
    7.4 3’SL
           7.4.1 SIGNIFICANCE OF 3’SL IN LANGUAGE DEVELOPMENT DURING EARLY CHILDHOOD
                    TABLE 25 3’SL: MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 26 3’SL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
                    TABLE 27 3’SL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2017–2021 (TONS)
                    TABLE 28 3’SL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (TONS)
    7.5 6’SL
           7.5.1 WIDE USAGE OF HMOS ACROSS INDUSTRIES
                    TABLE 29 6’SL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 30 6’SL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (USD MILLION)
                    TABLE 31 6’SL: HMO MARKET, BY REGION, 2017–2021 (TONS)
                    TABLE 32 6’SL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (TONS)

8 HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION (Page No. - 93)
    8.1 INTRODUCTION
          FIGURE 40 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
          TABLE 33 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY APPLICATION, 2017–2021 (USD MILLION)
          TABLE 34 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY APPLICATION, 2022–2027 (USD MILLION)
           8.1.1 EXTENSIVE R&D ACTIVITIES BY INFANT FORMULA MANUFACTURERS
                    TABLE 35 INFANT FORMULA: HMO MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 36 INFANT FORMULA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (USD MILLION)
    8.2 FUNCTIONAL FOOD & BEVERAGES
           8.2.1 ROLE OF FAST-PACED LIFESTYLE AND GROWING ADOPTION OF CONVENIENCE FOOD PRODUCTS IN THE GROWTH OF FUNCTIONAL
                    TABLE 37 FUNCTIONAL FOOD & BEVERAGES: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 38 FUNCTIONAL FOOD & BEVERAGES: MARKET, BY REGION, 2022–2027 (USD MILLION)
    8.3 FOOD SUPPLEMENTS
           8.3.1 GROWING HEALTH AWARENESS AND DEMAND FOR NUTRITION-RICH FOOD PRODUCTS
                    TABLE 39 FOOD SUPPLEMENTS: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 40 FOOD SUPPLEMENTS: MARKET, BY REGION, 2022–2027 (USD MILLION)
    8.4 OTHER APPLICATIONS
           8.4.1 WIDE USAGE OF HMOS ACROSS INDUSTRIES
                    TABLE 41 OTHER APPLICATIONS: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 42 OTHER APPLICATIONS: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2022–2027 (USD MILLION)

9 HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION (Page No. - 101)
    9.1 INTRODUCTION
          FIGURE 41 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022 VS. 2027 (USD MILLION)
          TABLE 43 HMO MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
          TABLE 44 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
    9.2 NEUTRAL
           9.2.1 RISING CONSUMER CONCERNS REGARDING GUT HEALTH AND IMMUNITY IN INFANTS
                    TABLE 45 NEUTRAL: MARKET FOR HUMAN MILK OLIGOSACCHARIDES, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 46 NEUTRAL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY REGION, 2022–2027 (USD MILLION)
    9.3 ACIDIC
           9.3.1 IMITATION OF HUMAN MILK IN PREMIUM INFANT FORMULAS
                    TABLE 47 ACIDIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (USD MILLION)
                    TABLE 48 ACIDIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2022–2027 (USD MILLION)

10 HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION (Page No. - 106)
     10.1 INTRODUCTION
             FIGURE 42 CHINA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE HUMAN MILK OLIGOSACCHARIDES MARKET IN 2022
             FIGURE 43 MARKET FOR HUMAN MILK OLIGOSACCHARIDES, BY REGION, 2022 VS. 2027 (USD MILLION)
             TABLE 49 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
             TABLE 50 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2022–2027 (USD MILLION)
             TABLE 51 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2017–2021 (TONS)
             TABLE 52 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION, 2022–2027 (TONS)
             TABLE 53 GLOBAL HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 54 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 55 GLOBAL HMO MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 56 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 57 GLOBAL HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 58 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 59 GLOBAL HMO MARKET, BY CONCENTRATION, 2017–2021(USD MILLION)
             TABLE 60 GLOBAL HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
     10.2 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: COVID-19 IMPACT ANALYSIS - BY REGION
             TABLE 61 REALISITIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY REGION, 2017–2022 (USD MILLION)
             TABLE 62 OPTIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY REGION, 2017–2022 (USD MILLION)
             TABLE 63 PESSIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE GLOBAL MARKET, BY REGION, 2017–2022 (USD MILLION)
     10.3 NORTH AMERICA
             FIGURE 44 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKETSNAPSHOT, 2022
             TABLE 64 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
             TABLE 65 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 66 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 67 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 68 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 69 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 70 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 71 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 72 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
             TABLE 73 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
             10.3.1 US
                        10.3.1.1 Increased demand from end-user companies, such as Nestlι S.A. (Switzerland) and Danone S.A. (France)
                                      TABLE 74 US: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 75 US: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY TYPE, 2022–2027 (USD MILLION)
             10.3.2 CANADA
                        10.3.2.1 Cronobacter Sakazakii or Salmonella Newport infection among infants hindering the Canadian human milk oligosaccharides (hmo) market
                                      TABLE 76 CANADA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 77 CANADA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.3.3 MEXICO
                        10.3.3.1 Rise in per capita expenditure on nutritious and healthy foods estimated to boost the market
                                      TABLE 78 MEXICO: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 79 MEXICO: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
     10.4 EUROPE
             TABLE 80 EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
             TABLE 81 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 82 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 83 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 84 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 85 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 86 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 87 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 88 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
             TABLE 89 EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
             10.4.1 GERMANY
                        10.4.1.1 Continuous research and development in the HMO segment
                                      TABLE 90 GERMANY: MARKET FOR HUMAN MILK OLIGOSACCHARIDES, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 91 GERMANY: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.4.2 UK
                        10.4.2.1 Introduction of HMO-based infant formulas
                                      TABLE 92 UK: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 93 UK: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.4.3 FRANCE
                        10.4.3.1 Strategic initiatives taken by local players
                                      TABLE 94 FRANCE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 95 FRANCE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.4.4 SPAIN
                        10.4.4.1 Consumer preference for clean-label ingredients paving the way for 2’FL dietary supplement products
                                      TABLE 96 SPAIN: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE,  2017–2021 (USD MILLION)
                                      TABLE 97 SPAIN: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.4.5 ITALY
                        10.4.5.1 Increasing popularity of HMO-based adult supplements
                                      TABLE 98 ITALY: MARKET FOR HUMAN MILK OLIGOSACCHARIDES, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 99 ITALY: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.4.6 REST OF EUROPE
                        10.4.6.1 Aggressive marketing around infant formulas and misleading health claims hindering human milk oligosaccharides market growth
                                      TABLE 100 REST OF EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 101 REST OF EUROPE: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
     10.5 ASIA PACIFIC
            FIGURE 45 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SNAPSHOT, 2022
             TABLE 102 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
             TABLE 103 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 104 ASIA PACIFIC: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 105 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 106 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 107 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 108 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 109 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 110 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
             TABLE 111 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
             10.5.1 CHINA
                        10.5.1.1 Continuous research & development in the field of HMO expected to expand the market
                                      TABLE 112 CHINA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 113 CHINA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.5.2 INDIA
                        10.5.2.1 Millennial population playing an important role in driving the demand for HMO-based food products
                                      TABLE 114 INDIA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 115 INDIA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.5.3 JAPAN
                        10.5.3.1 Stringent rules and regulations by the Japanese government bodies challenging human milk oligosaccharides market growth
                                      TABLE 116 JAPAN: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 117 JAPAN: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.5.4 AUSTRALIA & NEW ZEALAND
                        10.5.4.1 Approval for the use of 2’FL HMOs in infant formula
                                      TABLE 118 AUSTRALIA & NEW ZEALAND: MARKET FOR HUMAN MILK OLIGOSACCHARIDES, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 119 AUSTRALIA & NEW ZEALAND: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.5.5 REST OF ASIA PACIFIC
                        10.5.5.1 Strategic decisions undertaken
                                      TABLE 120 REST OF ASIA PACIFIC: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 121 REST OF ASIA PACIFIC: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
     10.6 SOUTH AMERICA
             TABLE 122 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
             TABLE 123 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 124 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 125 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 126 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 127 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 128 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 129 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 130 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
             TABLE 131 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
             10.6.1 BRAZIL
                        10.6.1.1 Infant formulas gaining popularity due to their ease of use
                                      TABLE 132 BRAZIL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 133 BRAZIL: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.6.2 ARGENTINA
                        10.6.2.1 Growing inclination toward functional food
                                      TABLE 134 ARGENTINA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET , BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 135 ARGENTINA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.6.3 REST OF SOUTH AMERICA
                        10.6.3.1 Influence of health and wellness trends
                                      TABLE 136 REST OF SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 137 REST OF SOUTH AMERICA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
     10.7 REST OF THE WORLD (ROW)
             TABLE 138 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
             TABLE 139 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
             TABLE 140 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
             TABLE 141 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             TABLE 142 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (TONS)
             TABLE 143 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (TONS)
             TABLE 144 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
             TABLE 145 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
             TABLE 146 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
             TABLE 147 ROW: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
             10.7.1 MIDDLE EAST
                        10.7.1.1 Complementary food feeding among infants
                                      TABLE 148 MIDDLE EAST: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 149 MIDDLE EAST: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2022–2027 (USD MILLION)
             10.7.2 AFRICA
                        10.7.2.1 Prevalence of vitamin deficiency among women and children
                                      TABLE 150 AFRICA: HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE, 2017–2021 (USD MILLION)
                                      TABLE 151 AFRICA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 156)
     11.1 OVERVIEW
     11.2 MARKET SHARE ANALYSIS, 2021
             TABLE 152 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: DEGREE OF COMPETITION
     11.3 KEY PLAYER STRATEGIES
     11.4 HISTORICAL REVENUE ANALYSIS OF KEY PLAYERS
             FIGURE 46 THREE-YEAR TOTAL REVENUE ANALYSIS OF KEY PLAYERS IN THE MARKET, 2019–2021 (USD BILLION)
     11.5 COVID-19-SPECIFIC COMPANY RESPONSE
             11.5.1 DSM
             11.5.2 BASF SE
             11.5.3 DUPONT
             11.5.4 CHR HANSEN HOLDING A/S
     11.6 COMPANY EVALUATION QUADRANT (KEY PLAYERS)
             11.6.1 STARS
             11.6.2 EMERGING LEADERS
             11.6.3 PERVASIVE PLAYERS
             11.6.4 PARTICIPANTS
                       FIGURE 47 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: COMPANY EVALUATION QUADRANT, 2021 (KEY PLAYERS)
     11.7 PRODUCT FOOTPRINT
             TABLE 153 COMPANY, BY TYPE FOOTPRINT
             TABLE 154 COMPANY, BY APPLICATION FOOTPRINT
             TABLE 155 COMPANY, BY REGIONAL FOOTPRINT
             TABLE 156 COMPANY, BY OVERALL FOOTPRINT
     11.8 START-UP/SME EVALUATION QUADRANT (OTHER PLAYERS)
             11.8.1 PROGRESSIVE COMPANIES
             11.8.2 STARTING BLOCKS
             11.8.3 RESPONSIVE COMPANIES
             11.8.4 DYNAMIC COMPANIES
                        TABLE 157 DETAILED LIST OF KEY STARTUP/SMES
                        TABLE 158 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SMES
                        FIGURE 48 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: COMPANY EVALUATION QUADRANT, 2021 (OTHER PLAYERS)
     11.9 COMPETITIVE SCENARIO
             11.9.1 NEW PRODUCT LAUNCHES
                        TABLE 159 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: NEW PRODUCT LAUNCHES, 2018–2021
             11.9.2 DEALS
                        TABLE 160 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET: DEALS, 2018–2021

12 COMPANY PROFILES (Page No. - 172)
     12.1 KEY PLAYERS
(Business overview, Products offered, Recent Developments, MNM view)*
             12.1.1 DSM
                        TABLE 161 DSM: BUSINESS OVERVIEW
                        FIGURE 49 DSM: COMPANY SNAPSHOT
                        TABLE 162 DSM: PRODUCTS OFFERED
                        TABLE 163 DSM: DEALS
             12.1.2 BASF SE.
                        TABLE 164 BASF SE.: BUSINESS OVERVIEW
                        FIGURE 50 BASF SE.: COMPANY SNAPSHOT
                        TABLE 165 BASF SE.: PRODUCTS OFFERED
                        TABLE 166 BASF SE: NEW PRODUCT LAUNCHES
                        TABLE 167 BASF SE.: DEALS
             12.1.3 CHR HANSENHOLDING A/S
                        TABLE 168 CHR HANSEN HOLDING A/S: BUSINESS OVERVIEW
                        FIGURE 51 CHR. HANSEN HOLDINGS A/S: COMPANY SNAPSHOT
                        TABLE 169 CHR. HANSEN HOLDINGS A/S: PRODUCTS OFFERED
                        TABLE 170 CHR. HANSEN HOLDING A/S: DEALS
             12.1.4 DUPONT
                        TABLE 171 DUPONT: BUSINESS OVERVIEW
                        FIGURE 52 DUPONT: COMPANY SNAPSHOT
                        TABLE 172 DUPONT: PRODUCTS OFFERED
                        TABLE 173 DUPONT: NEW PRODUCT LAUNCHES
                        TABLE 174 DUPONT: DEALS
             12.1.5 NESTLE
                        TABLE 175 NESTLE: BUSINESS OVERVIEW
                        FIGURE 53 NESTLE: COMPANY SNAPSHOT
                        TABLE 176 NESTLE: PRODUCTS OFFERED
                        TABLE 177 NESTLE: NEW PRODUCT LAUNCHES
             12.1.6 BIOSYNTH CARBOSYNTH
                        TABLE 178 BIOSYNTH CARBOSYNTH: BUSINESS OVERVIEW
                        TABLE 179 BIOSYNTH CARBOSYNTH: PRODUCTS OFFERED
                        TABLE 180 BIOSYNTH CARBOSYNTH: DEALS
             12.1.7 INBIOSE NV.
                        TABLE 181 INBIOSE NV.: BUSINESS OVERVIEW
                        TABLE 182 INBIOSE NV: PRODUCTS OFFERED
             12.1.8 GNUBIOTICS SCIENCES S.A.
                        TABLE 183 GNUBIOTICS SCIENCES S.A.: BUSINESS OVERVIEW
                        TABLE 184 GNUBIOTICS SCIENCES S.A.: PRODUCTS OFFERED
                        TABLE 185 GNUBIOTICS SCIENCES S.A.: NEW PRODUCT LAUNCHES
             12.1.9 ABBOTT LABORATORIES
                        TABLE 186 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 54 ABBOTT LABORATORIES: COMPANY SNAPSHOT
                        TABLE 187 ABBOTT LABORATORIES: PRODUCTS OFFERED
                        TABLE 188 ABBOTT LABORATORIES: NEW PRODUCT LAUNCHES
             12.1.10 ROYAL FRIESLANDCAMPINA N.V
                        TABLE 189 ROYAL FRIESLANDCAMPINA N.V: BUSINESS OVERVIEW
                        FIGURE 55 ROYAL FRIESLANDCAMPINA N.V: COMPANY SNAPSHOT
                        TABLE 190 ROYAL FRIESLANDCAMPINA N.V: PRODUCTS OFFERED
                        TABLE 191 ROYAL FRIESLANDCAMPINA N.V: NEW PRODUCT LAUNCHES
                        TABLE 192 ROYAL FRIESLANDCAMPINA N.V: DEALS
             12.1.11 ELICITYL S.A
                        TABLE 193 ELICITYL S.A.: BUSINESS OVERVIEW
                        TABLE 194 ELICITYL S.A: PRODUCTS OFFERED
             12.1.12 DEXTRA LABORATORIES LTD.
                        TABLE 195 DEXTRA LABORATORIES LTD.: BUSINESS OVERVIEW
                        TABLE 196 DEXTRA LABORATORIES LTD.: PRODUCTS OFFERED
     12.2 START-UPS/SME’S/OTHER PLAYERS
             12.2.1 ZUCHEM INC.
                        TABLE 197 ZUCHEM INC.: COMPANY OVERVIEW
             12.2.2 ADVANCED PROTEIN TECHNOLOGIES CORP.
                        TABLE 198 ADVANCED PROTEIN TECHNOLOGIES CORP.: COMPANY OVERVIEW
             12.2.3 CONAGEN INC.
                        TABLE 199 CONAGEN INC.: COMPANY OVERVIEW
             12.2.4 KYOWA HAKKO BIO CO. LTD.
                        TABLE 200 KYOWA HAKKA BIO CO. LTD.: COMPANY OVERVIEW
             12.2.5 MEDOLAC LABORATORIES
                        TABLE 201 MEDOLAC LABORATORIES: COMPANY OVERVIEW
     12.3 END USER COMPANY PROFILES
             12.3.1 H & H GROUP
                        TABLE 202 H&H GROUP: BUSINESS OVERVIEW
                        TABLE 203 H&H GROUP: PRODUCTS OFFERED
             12.3.2 LAYER ORIGIN NUTRITION
                        TABLE 204 LAYER ORIGIN NUTRITION: BUSINESS OVERVIEW
                        TABLE 205 LAYER ORIGIN NUTRITION: PRODUCTS OFFERED
             12.3.3 STANDARD PROCESS INC.
                        TABLE 206 STANDARD PROCESS INC.: BUSINESS OVERVIEW
                        TABLE 207 STANDARD PROCESS INC.: PRODUCTS OFFERED
             12.3.4 RECKITT BENCKISER GROUP
                        TABLE 208 RECKITT BENCKISER GROUP: BUSINESS OVERVIEW
                        TABLE 209 RECKITT BENCKISER GROUP: PRODUCTS OFFERED
             12.3.5 AMAZON
                        TABLE 210 AMAZON: BUSINESS OVERVIEW
                        TABLE 211 AMAZON: PRODUCTS OFFERED

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 ADJACENT & RELATED MARKETS (Page No. - 210)
     13.1 INTRODUCTION
     13.2 INFANT FORMULA INGREDIENTS MARKET
             13.2.1 LIMITATIONS
             13.2.2 MARKET DEFINITION
             13.2.3 MARKET OVERVIEW
             13.2.4 INFANT FORMULA INGREDIENTS MARKET, BY INGREDIENT
                        TABLE 212 INFANT FORMULA INGREDIENTS MARKET SIZE, BY INGREDIENT, 2017–2025 (USD MILLION)
                        TABLE 213 INFANT FORMULA INGREDIENTS MARKET SIZE, BY INGREDIENT, 2017–2025 (KT)
             13.2.5 INFANT FORMULA INGREDIENTS MARKET, BY REGION
                        TABLE 214 INFANT FORMULA INGREDIENTS MARKET SIZE, BY REGION, 2017–2025 (USD BILLION)
                        TABLE 215 INFANT FORMULA INGREDIENTS MARKET SIZE, BY REGION, 2017–2025 (KT)
     13.3 FUNCTIONAL FOOD INGREDIENTS MARKET
             13.3.1 LIMITATIONS
             13.3.2 MARKET DEFINITION
             13.3.3 MARKET OVERVIEW
             13.3.4 FUNCTIONAL FOOD INGREDIENTS MARKET, BY TYPE
                        TABLE 216 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016–2020 (USD MILLION)
                        TABLE 217 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2021–2026 (USD MILLION)
             13.3.5 FUNCTIONAL FOOD INGREDIENTS MARKET, BY REGION
                        TABLE 218 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY REGION, 2016–2020 (USD MILLION)
                        TABLE 219 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY REGION, 2021–2026 (USD MILLION)


14 APPENDIX (Page No. - 220)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This research study involved the extensive use of secondary sources—directories and databases such as Bloomberg Businessweek and Factiva—to identify and collect information useful for a technical, market-oriented, and commercial study of the Human Milk Oligosaccharides (HMO) Market. In-depth interviews were conducted with various primary respondents—such as key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants—to obtain and verify critical qualitative and quantitative information as well as to assess prospects. The following figure depicts the research design applied in drafting this report on the HMO market.

Secondary Research

In the secondary research process, various sources such as annual reports, press releases & investor presentations of companies, white papers, food journals, certified publications, articles from recognized authors, gold & silver standard websites, directories, and databases, were referred to identify and collect information.

Secondary research was mainly used to obtain key information about the industry’s supply chain, the total pool of key players, and market classification and segmentation as per the industry trends to the bottom-most level, regional markets, and key developments from both market- and technology oriented perspectives.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information. The primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the HMO market.

Hmo Market Primary Respondents

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both the top-down and bottom-up approaches have been used to estimate and validate the total size of the human milk oligosaccharides (HMO) market. These approaches were extensively to determine the size of the subsegments in the market. The research methodology used to estimate the market size includes the following details:

  • Top-down approach:
    • The key players in the industry and the market were identified through extensive secondary research.
    • The industry's supply chain and market size were determined through primary and secondary research.
    • All percentage share splits and breakdowns were determined using secondary sources and verified through primary sources.
    • The parent market—infant formula ingredients market—was considered to validate the market details of human milk oligosaccharides (HMO) further.
  • Bottom-up approach:
    • The market sizes were analyzed based on the share of each type of human milk oligosaccharides (HMO) at regional and country levels. Thus, the global market for HMO was estimated with a bottom-up approach of the type at the country level.
    • Based on the demand from each application, offerings of key players, and the region-wise market share of major players, the global market for the application was estimated.
    • Other factors include penetration rate of HMO in end-user applications, such as infant formulas, food supplements, and functional food & beverages; consumer awareness; and function trends; pricing trends; the adoption rate and price factors; patents registered; and organic and inorganic growth attempts.
    • All macroeconomic and microeconomic factors affecting the growth of the human milk oligosaccharides (HMO) market were considered while estimating the market size.
    • All possible parameters that affect the market covered in this research study were accounted for, viewed in extensive detail, verified through primary research, and analyzed to obtain final quantitative and qualitative data.

The following sections (bottom-up & top-down) (supply-demand) depict the overall market size estimation process employed for this study.

Data Triangulation

After arriving at the overall market size from the estimation process explained above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size was validated using the top-down and bottom-up approaches.

Report Objectives

  • Market Intelligence
    • Determining and projecting the size of the human milk oligosaccharides market based on type, application, concentration, and region, over a six-year period, ranging from 2022 to 2027
    • Identifying attractive opportunities in the market by determining the largest and fastest-growing segments across regions
    • Analyzing the demand-side factors based on the following:
      • Impact of macro- and micro-economic factors on the market
      • Shift in demand patterns across different subsegments and regions
  • Competitive Intelligence
    • Identifying and profiling the key market players in the HMO market
    • Determining the share of key players operating in the HMO market
    • Providing a comparative analysis of the market leaders on the basis of the following:
      • Product offerings
      • Business strategies
      • Strengths, weaknesses, opportunities, and threats
      • Key financials
    • Understanding the competitive landscape and identifying the major growth strategies adopted by the key companies
    • Analyzing the patents registered and regulatory frameworks across regions and their impact on prominent market players
    • Analyzing the market dynamics and competitive situations & trends across regions and their impact on prominent market players

Available Customizations

With the given market data, MarketsandMarkets offers customizations according to company-specific scientific needs.

The following customization options are available for the report:

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolio of each company

Geographic Analysis

With the given market data, MarketsandMarkets offers customizations according to the company-specific scientific needs.

  • Further breakdown of the Rest of Europe market for HMO into the Greece
  • Further breakdown of the Rest of South America market for HMO into Chile, Peru, and Ecuador
  • Further breakdown of other countries in the RoW market for HMO into Egypt, Israel, and Turkey

Company Information

  • Detailed analyses and profiling of additional market players (up to five)
Report Code
FB 8086
Published ON
Apr, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Human Milk Oligosaccharides (HMO) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback